Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) saw a significant decline in short interest in March. As of March 15th, there was short interest totalling 868,800 shares, a decline of 67.6% from the February 28th total of 2,680,000 shares. Approximately 17.9% of the shares of the stock are short sold. Based on an average daily volume of 5,360,000 shares, the days-to-cover ratio is presently 0.2 days.

Quoin Pharmaceuticals Stock Up 4.9 %

Shares of QNRX stock opened at $0.30 on Thursday. The stock has a market cap of $1.49 million, a P/E ratio of -0.07 and a beta of 1.82. Quoin Pharmaceuticals has a fifty-two week low of $0.27 and a fifty-two week high of $1.57. The business has a fifty day simple moving average of $0.34 and a 200-day simple moving average of $0.54.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its earnings results on Thursday, March 13th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.15. On average, sell-side analysts anticipate that Quoin Pharmaceuticals will post -2.05 earnings per share for the current year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Apollon Wealth Management LLC purchased a new stake in shares of Quoin Pharmaceuticals in the fourth quarter valued at $52,000. Boothbay Fund Management LLC purchased a new position in Quoin Pharmaceuticals in the 4th quarter valued at about $53,000. Renaissance Technologies LLC boosted its stake in shares of Quoin Pharmaceuticals by 244.1% during the 4th quarter. Renaissance Technologies LLC now owns 133,122 shares of the company’s stock worth $87,000 after purchasing an additional 94,431 shares during the last quarter. Finally, Altium Capital Management LLC purchased a new stake in shares of Quoin Pharmaceuticals during the fourth quarter worth about $184,000. Hedge funds and other institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.